Home > Journals > International Angiology > Past Issues > International Angiology 2001 June;20(2) > International Angiology 2001 June;20(2):164-73





A Journal on Angiology

Official Journal of the International Union of Angiology, the International Union of Phlebology and the Central European Vascular Forum
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,899




International Angiology 2001 June;20(2):164-73

language: English

The in vitro effect of a low molecular weight heparin, nadroparin (Fraxiparine), on leukocytes obtained from patients with vascular diseases

Neagu M., Manda G., Constantin C., Tanaseanu C. *, Mikhailidis D. P. **

From the Immunobiology Department, Victor Babes Institute, Bucharest, Romania
* Sfantul Pantelimon Hospital, Medical Section 2, Bucharest, Romania
** Department of Molecular Pathology and Clinical Biochemistry, Royal Free Hospital, London, United Kingdom


Background. Both lym­pho­cytes and gran­u­loc­y­tes may play a role in the ­immune ­system-medi­at­ed inflam­ma­to­ry ­response asso­ciat­ed with non-Q wave infarc­tion and aor­tic aneu­rysms.
Methods. The pur­pose of this study was to estab­lish the in vitro ­effects of a low molec­u­lar ­weight hep­ar­in (LMWH), nadrop­ar­in (Fraxiparine), on some func­tion­al param­e­ters of periph­er­al gran­u­loc­y­tes and lym­pho­cytes iso­lat­ed from con­trol sub­jects and ­patients with aor­tic aneu­rysm or non-Q wave infarc­tion.
Results. Nadroparin (0.06-600 AXaU/ml) exert­ed dif­fer­ent in vitro ­effects on gran­u­loc­y­tes and lym­pho­cytes iso­lat­ed from nor­mal sub­jects and the ­patient ­groups. The fol­low­ing indi­ces were ­assessed: super­ox­ide anion ­release, lym­pho­cyte pro­life­ra­tion, phag­o­cyt­ic activ­ity and the cel­lu­lar res­pir­a­to­ry burst. The ­effects of nadrop­ar­in var­ied accord­ing to the ­patient group and the index of lym­pho­cyte/gra­nu­lo­cyte ­assessed.
Conclusions. Since periph­er­al gran­u­loc­y­tes iso­lat­ed from these ­patients are acti­vat­ed, the ­observed inhi­bi­tion exert­ed by nadrop­ar­in on super­ox­ide anion ­release may be ben­e­fi­cial. LMWHs have addi­tion­al ­effects that are inde­pen­dent of their anti­co­ag­u­lant activ­ity. These ­effects may influ­ence the “inflam­ma­to­ry com­po­nent” of the ath­e­ros­cle­rot­ic pro­cess.

top of page

Publication History

Cite this article as

Corresponding author e-mail